Loading patent…
AssigneeMayo Foundation for Medical Education and Research
InventorsHaifei Jiang, Stephen James Russell
Estimating the term…
This document relates to methods and materials involved in treating a mammal (e.g., a human) having cancer and/or an infectious disease. For example, this document provides recombinant human cytomegalovirus (hCMV) vectors that include (e.g., are designed to include) nucleic acid encoding a viral gene transfer vector genome (e.g., a heterologous viral gene transfer vector genome) and one or more nucleic acids encoding a packaging polypeptide such that a cell of a mammal that is infected with the hCMV vector can produce and release the viral vector (e.g., an infectious lentiviral vector) which can then infect cells (e.g., immune cells) in vivo and can, optionally, drive expression of an exogenous polypeptide (e.g., a therapeutic polypeptide or an antigen receptor such as a chimeric antigen receptor (CAR)) in the infected immune cells within a mammal (e.g., a human) to induce an immune response within the mammal are provided.
A recombinant human cytomegalovirus (hCMV) vector capable of infecting a cell of a mammal, wherein said hCMV vector comprises heterologous nucleic acid encoding (i) a heterologous viral gene transfer vector genome and (ii) one or more helper polypeptides for amplifying and packaging said heterologous viral gene transfer vector genome into infectious vector particles, wherein said cell infected with said hCMV vector produces and releases said infectious vector particles comprising said gene transfer vector genome.
(canceled)
(canceled)
14-15. (canceled)
A method for treating a mammal having cancer, wherein said method comprises administering a recombinant hCMV vector to said mammal, wherein said hCMV vector is capable of infecting a cell of said mammal, wherein said hCMV comprises heterologous nucleic acid encoding (i) a heterologous viral gene transfer vector genome comprising a nucleic acid sequence encoding an antigen receptor polypeptide targeting a cancer antigen of said cancer and (ii) one or more helper polypeptides for amplifying and packaging said heterologous viral gene transfer vector genome into infectious vector particles, wherein said cell infected with said hCMV produces and releases said infectious vector particles comprising said gene transfer vector genome, and wherein said released infectious vector particles are capable of infecting an immune cell within said mammal and directing expression of said antigen receptor polypeptide by said infected immune cell, and wherein said infected immune cell expressing said antigen receptor reduces the number of cancer cells within said mammal.
23-35. (canceled)
A method for treating a mammal having an infectious disease, wherein said method comprises administering a recombinant hCMV vector to said mammal, wherein said hCMV vector is capable of infecting a cell of said mammal, wherein said hCMV vector comprises heterologous nucleic acid encoding (i) a heterologous viral gene transfer vector genome derived from a virus causing the infectious disease and (ii) one or more helper polypeptides for amplifying and packaging said heterologous viral gene transfer vector genome into infectious vector particles, wherein said cell infected with said hCMV vector produces and releases said infectious vector particles comprising said gene transfer vector genome, and wherein said infectious vector particles are recognized by an antigen presenting cell (APC) within said mammal such that said APC presents an antigen from said viral gene transfer vector to a T cell within said mammal, and wherein said T cell recognizes and destroys the virus causing the infectious disease within said mammal.
38-52. (canceled)
Dependencies are inferred from the claim text.